论文部分内容阅读
目的研究DCC基因对人卵巢癌细胞系HO-8910细胞在体外、体内化疗药物敏感性的影响。方法采用脂质体转染法将含有DCC基因的真核表达载体pcDNA3.1(+)-DCC导入人卵巢癌细胞系HO-8910中,逆转录-聚合酶链反应(RT-PCR)以及免疫组化法检测DCC基因表达情况。四甲基偶氮唑蓝(MTT)法测定经梯度浓度紫杉醇处理后的细胞存活率。体内观察DCC基因转染后裸鼠移植瘤对紫杉醇化疗的反应。结果 DCC基因可在HO-8910细胞中稳定表达。转染DCC基因后的HO-8910细胞经梯度浓度紫杉醇处理后细胞存活率显著低于对照组。HO-8910-DCC裸鼠移植瘤化疗组重量抑瘤率和体积抑瘤率均明显高于对照组。结沦DCC基因可增强HO-8910细胞在体外和体内对化疗药物的敏感性。
Objective To investigate the effect of DCC gene on chemosensitivity of human ovarian cancer cell line HO-8910 in vitro and in vivo. Methods The eukaryotic expression vector pcDNA3.1 (+) - DCC containing DCC gene was transfected into human ovarian cancer cell line HO-8910 by lipofectamine. RT - PCR and immunofluorescence DCC gene expression was detected by histochemistry. MTT assay was used to determine cell viability after paclitaxel treatment with gradient concentration. In vivo observation of DCC gene transfection in nude mice xenograft tumor response to chemotherapy. Results The DCC gene was stably expressed in HO-8910 cells. The survival rate of HO-8910 cells transfected with DCC gene was significantly lower than that of the control group after treated with paclitaxel in a gradient concentration. The weight inhibition rate and volume inhibition rate of HO-8910-DCC transplanted tumor in nude mice were significantly higher than those in control group. Knockdown DCC gene can enhance HO-8910 cells in vitro and in vivo chemosensitivity.